<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000657</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 140</org_study_id>
    <secondary_id>11115</secondary_id>
    <nct_id>NCT00000657</nct_id>
  </id_info>
  <brief_title>Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex</brief_title>
  <official_title>Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To compare the safety and effectiveness of orally administered didanosine (ddI) with high&#xD;
      dose orally administered zidovudine (AZT) in patients who develop or exhibit progression of&#xD;
      the AIDS dementia complex (ADC) and who have not previously been intolerant to AZT at doses&#xD;
      of up to 1000 mg/day.&#xD;
&#xD;
      HIV-infected or AIDS patients may develop ADC which causes damage to the nervous system. ADC&#xD;
      may be caused by some action of the AIDS virus on the nervous system, although similar&#xD;
      problems can be caused by other infections because the AIDS virus lowers the body's ability&#xD;
      to fight other infections. It is important to determine whether symptoms are due to ADC or to&#xD;
      some other infection since treatment varies for different conditions. AZT has been shown to&#xD;
      be beneficial to people with ADC although its effectiveness has only been studied in a small&#xD;
      number of patients. Studies suggest that higher doses of AZT are more likely to be effective&#xD;
      than standard doses in improving symptoms of ADC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-infected or AIDS patients may develop ADC which causes damage to the nervous system. ADC&#xD;
      may be caused by some action of the AIDS virus on the nervous system, although similar&#xD;
      problems can be caused by other infections because the AIDS virus lowers the body's ability&#xD;
      to fight other infections. It is important to determine whether symptoms are due to ADC or to&#xD;
      some other infection since treatment varies for different conditions. AZT has been shown to&#xD;
      be beneficial to people with ADC although its effectiveness has only been studied in a small&#xD;
      number of patients. Studies suggest that higher doses of AZT are more likely to be effective&#xD;
      than standard doses in improving symptoms of ADC.&#xD;
&#xD;
      Patients are randomly assigned to receive either oral ddI or oral AZT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 1992</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>80</enrollment>
  <condition>AIDS Dementia Complex</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Chronic suppressive therapy for herpes simplex virus, cytomegalovirus, Candida&#xD;
             albicans, and Salmonella.&#xD;
&#xD;
          -  Prophylactic therapy for Pneumocystis carinii pneumonia.&#xD;
&#xD;
          -  Maintenance anticonvulsant therapy following a seizure in the context of the AIDS&#xD;
             dementia complex.&#xD;
&#xD;
          -  Isoniazid only if no acceptable alternative therapy is available.&#xD;
&#xD;
          -  Judicious use of benzodiazepines, tricyclics, and other antidepressants is allowed but&#xD;
             a stable dose level should be obtained prior to entry and maintained throughout the&#xD;
             trial.&#xD;
&#xD;
          -  In patients for whom it is medically necessary to initiate or alter therapy with these&#xD;
             drugs during the initial 16 week study period, data will not be used in the study.&#xD;
&#xD;
          -  Metronidazole for single courses of therapy not to exceed 14 days within consecutive&#xD;
             90-day intervals, the first of which begins at the initiation of the study.&#xD;
&#xD;
          -  Erythropoietin for patients under the relevant Treatment IND.&#xD;
&#xD;
          -  Symptomatic therapies (such as analgesics, antihistamines, antiemetics, antidiarrheal&#xD;
             agents).&#xD;
&#xD;
        Allowed but not encouraged:&#xD;
&#xD;
          -  trimethoprim /sulfamethoxazole (T/S) or other sulfonamides.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Screened for other causes of dementia.&#xD;
&#xD;
          -  Stage 1, 2, or 3 AIDS dementia complex.&#xD;
&#xD;
          -  Estimated premorbid IQ of at least 70.&#xD;
&#xD;
          -  Anti-HIV antibody or HIV in blood and/or cerebrospinal fluid.&#xD;
&#xD;
          -  If prior history of positive syphilis serology, should have been treated with&#xD;
             appropriate course of antibiotics; if not, such treatment should be administered prior&#xD;
             to pretreatment screening.&#xD;
&#xD;
          -  Not have previously shown intolerance to zidovudine (AZT).&#xD;
&#xD;
          -  Able (or parent and/or guardian able) to provide written consent.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Basal cell carcinoma, in situ carcinoma of the cervix, Kaposi's sarcoma without&#xD;
             evidence of visceral involvement or not requiring systemic chemotherapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Grade 3 neuropathy, based on the Neuropathy Targeted Symptom.&#xD;
&#xD;
          -  Questionnaire, or patients with any moderate abnormality indicative of peripheral&#xD;
             neuropathy including stocking loss of sensation (to sharp pain, light touch, or&#xD;
             vibration), distal extremity weakness (&lt; 4/5), or absent ankle jerks.&#xD;
&#xD;
          -  History of present or past acute or chronic pancreatitis.&#xD;
&#xD;
          -  Active, symptomatic AIDS-defining opportunistic infection and requiring any ongoing&#xD;
             maintenance therapy for confounding neurologic disease.&#xD;
&#xD;
          -  Severe premorbid psychiatric illness including bipolar illness, schizophrenia, and&#xD;
             electroconvulsive therapy.&#xD;
&#xD;
        Previous neurological disease unrelated to HIV infection:&#xD;
&#xD;
          -  multiple sclerosis, documented stroke, degenerative disease.&#xD;
&#xD;
          -  Patients with chronic seizure disorders or head injury will only be excluded if the&#xD;
             condition results in functional impairment or is likely to interfere with the&#xD;
             evaluation.&#xD;
&#xD;
          -  Concurrent or previous central nervous system infections or neoplasms as revealed by&#xD;
             Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI) scan or cerebrospinal&#xD;
             fluid analysis (such as toxoplasmosis, primary or metastatic Central Nervous System&#xD;
             (CNS) lymphoma, progressive multifocal leukoencephalopathy, cryptococcal or other&#xD;
             fungal meningitis, tuberculous Central Nervous System (CNS) infections, and untreated&#xD;
             neurosyphilis).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Intravenous pentamidine. DHPG (Ganciclovir) should not be co-administered.&#xD;
&#xD;
          -  Monoamine oxidase (MAO) inhibitors, phenothiazines, butyrophenones, barbiturates,&#xD;
             amphetamines.&#xD;
&#xD;
          -  Oral acidifying agents.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Neoplasms not specifically allowed.&#xD;
&#xD;
          -  Grade 3 neuropathy.&#xD;
&#xD;
          -  History of present or past acute or chronic pancreatitis.&#xD;
&#xD;
          -  Active, symptomatic AIDS-defining opportunistic infection.&#xD;
&#xD;
          -  Requiring any ongoing maintenance therapy for confounding neurologic disease.&#xD;
&#xD;
          -  Conditions listed under Exclusion Co-existing Conditions.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Anti-HIV therapy other than zidovudine (AZT).&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Corticosteroids.&#xD;
&#xD;
          -  Drugs toxic to peripheral nerves.&#xD;
&#xD;
          -  Investigative drugs.&#xD;
&#xD;
          -  Neurotoxic drugs.&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Dideoxycytidine (ddC).&#xD;
&#xD;
        Active alcohol or drug abuse or methadone maintenance sufficient, in the investigator's&#xD;
        opinion, to prevent adequate compliance with study therapy and evaluations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C Hall</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco AIDS Clinic / San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ Hosp</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>462025250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charity Hosp / Tulane Univ Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State Univ Med Ctr / Tulane Med School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>981224304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brouwers P, Hendricks M, Lietzau JA, Pluda JM, Mitsuya H, Broder S, Yarchoan R. Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens. AIDS. 1997 Jan;11(1):59-66. doi: 10.1097/00002030-199701000-00009.</citation>
    <PMID>9110076</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Didanosine</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Drugs, Investigational</keyword>
  <keyword>AIDS Dementia Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>AIDS Dementia Complex</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

